A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With GEP-NET
← catalyst calendarNCT05050942 · readout ≤ 103 d
Sponsored by Camurus AB (industry) · CAMX.ST — their whole pipeline →.
Phase
Phase 3
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
332actual
Sites
86
Countries
Australia, Belgium, Canada +9
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2021-10-22 | actual | When the study began enrolling |
| Primary completion | Nov 2026 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Nov 2028 | estimated | The whole study's end, after follow-up |
| First posted | 2021-09-21 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-28 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Gastro-enteropancreatic Neuroendocrine Tumor
Interventions
- Drug: CAM2029
- Drug: Octreotide LAR
- Drug: Lanreotide ATG
Primary outcome
what the primary-completion date above is the date OFProgression-free survival (PFS) as assessed by a Blinded Independent Review Committee (BIRC)
measured From date of randomization until disease progression or death due to any cause, whichever comes first, assessed up to 48 months
Publications
- PMID 38229199 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · CAMX.ST's whole pipeline · Catalyst calendar · Every registered study · What changed